Subgroup analysis based on age, smoking status, tumor stage, PD-L1 expression level, and whether or not to combine chemotherapy revealed no significant difference in PFS between patients in the sintilimab and pembrolizumab groups (Figure 2A). This evidence concerns the gene CD274 and neoplasm.